fingolimod hydrochloride has been researched along with Herpes Zoster in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aramideh Khouy, R; Bokharaei-Salim, F; Esghaei, M; Etemadifar, M; Karampoor, S; Keyvani, H; Monavari, SH; Taghinezhad, S | 1 |
| Derfuss, T; Fischer-Barnicol, B; Kappos, L; Kuhle, J; Lindberg, RL; Lorscheider, J; Mehta, SK; Paroz, C; Pierson, DL; Ricklin, ME; Sprenger, T; Waschbisch, A | 1 |
| Corral, I; Costa-Frossard, L; Kawiorski, MM; Viedma-Guiard, E | 1 |
| Arvin, AM; Bezuidenhoudt, M; Gershon, A; Gershon, M; Kappos, L; Levin, MJ; Morris, MI; Putzki, N; Reder, AT; Tornatore, C; Wolinsky, JS | 1 |
| Tyler, KL | 1 |
| Fernández Fournier, M; Gómez Fernández, C; González Ramos, J; Herranz Pinto, P; Mayor Ibarguren, A; Romero Gómez, MP; Tallón Barranco, A | 1 |
| Afazel, S; Harrer, A; Haschke-Becher, E; Kraus, J; Oppermann, K; Pilz, G; Sellner, J; Trinka, E; Wipfler, P | 1 |
| Tanaka, M | 1 |
| Akeda, Y; Hagiya, H; Iida, T; Motooka, D; Nakamura, S; Shimizu, M; Tomono, K; Yamamoto, N; Yoshida, H | 1 |
| Bassetti, M; Ginocchio, F; Mancardi, GL; Uccelli, A | 1 |
| Bourdette, D; Gilden, D | 1 |
| Baumgartner, A; Gross, CM; Rauer, S; Stich, O | 1 |
1 trial(s) available for fingolimod hydrochloride and Herpes Zoster
| Article | Year |
|---|---|
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Consensus; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Incidence; Male; Medication Reconciliation; Middle Aged; Product Surveillance, Postmarketing; Propylene Glycols; Risk Assessment; Risk Factors; Severity of Illness Index; Sphingosine; Young Adult | 2015 |
11 other study(ies) available for fingolimod hydrochloride and Herpes Zoster
| Article | Year |
|---|---|
The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
Topics: Adult; Case-Control Studies; Female; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Seroepidemiologic Studies | 2019 |
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Topics: Adult; Aged; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Herpes Zoster; Herpesvirus 3, Human; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Saliva; Sphingosine; T-Lymphocytes; Virus Activation | 2013 |
Polydermatomal perineal and gluteal herpes zoster infection in a patient on fingolimod treatment.
Topics: Adult; Buttocks; Female; Fingolimod Hydrochloride; Genital Diseases, Female; Herpes Zoster; Humans; Immunosuppressive Agents; Multiple Sclerosis; Perineum | 2015 |
Fingolimod and risk of varicella-zoster virus infection: back to the future with an old infection and a new drug.
Topics: Female; Fingolimod Hydrochloride; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Male; Medication Reconciliation; Propylene Glycols; Sphingosine | 2015 |
Herpes zoster: a potential risk associated with fingolimod treatment.
Topics: Acyclovir; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Follow-Up Studies; Herpes Zoster; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Recurrence; Risk Assessment; Treatment Outcome; Valacyclovir; Valine | 2015 |
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Topics: Adaptive Immunity; Adult; Antibodies, Viral; Cytokines; Fingolimod Hydrochloride; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Male; Multiple Sclerosis; Phenotype; Virus Activation | 2015 |
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Topics: Adult; Aged; Female; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunocompromised Host; Immunosuppressive Agents; Incidence; Male; Middle Aged; Multiple Sclerosis; Recurrence; Secondary Prevention | 2016 |
Herpes zoster laryngitis in a patient treated with fingolimod.
Topics: Acyclovir; Adult; Female; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunosuppressive Agents; Laryngitis; Virus Activation | 2016 |
Primary varicella zoster infection associated with fingolimod treatment.
Topics: Acyclovir; Adult; Female; Fingolimod Hydrochloride; Herpes Zoster; Herpesvirus 3, Human; Humans; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome | 2011 |
Fingolimod and multiple sclerosis: four cautionary tales.
Topics: Antibodies, Monoclonal, Humanized; Brain; Cerebrovascular Disorders; Encephalitis, Varicella Zoster; Female; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Male; Multiple Sclerosis; Natalizumab; Nerve Fibers, Myelinated; Propylene Glycols; Sphingosine | 2012 |
Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.
Topics: Adult; Anti-Inflammatory Agents; Brain; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |